

Industry DNA Sampling


Q1 Please insert the survey code you were given by Covington & Burling (Jenny Green) This code will be used only to assure that each company submits only one response, and to remind companies about submitting the survey. The code key will be maintained only by Covington and Burling (Legal Monitor) and will not be shared with members of the I-PWG.

Answered: 16 Skipped: 0

Industry DNA Sampling

Q2 What were the pharmaceutical R&D expenses of your company in 2008?

Answered: 15 Skipped: 1




ANSWER CHOICES	RESPONSES
Less than 1 billion US dollars	13.33% 2
1-2 billion US dollars	6.67% 1
More than 2 billion US dollars	80.00% 12
TOTAL	15


Industry DNA Sampling

Q3 Please indicate how frequently DNA samples are collected in Clinical Trials conducted by your company: Please base your answers on trials initiated and completed since 2003 across several therapeutic areas. Please base your answers on actual data using the following calculation:
 $(\# \text{ of trials with DNA collection}) / (\# \text{ of trials conducted})$

Answered: 15 Skipped: 1



Industry DNA Sampling




	<10%	10-49%	50-69%	70-90%	>90%	DO NOT KNOW	NOT APPLICABLE	TOTAL
Phase I (Healthy Volunteers)	0.00% 0	40.00% 6	6.67% 1	6.67% 1	33.33% 5	0.00% 0	13.33% 2	15
Phase I (Diseased Patients)	26.67% 4	33.33% 5	6.67% 1	6.67% 1	26.67% 4	0.00% 0	0.00% 0	15
Phase II	13.33% 2	40.00% 6	13.33% 2	20.00% 3	13.33% 2	0.00% 0	0.00% 0	15
Phase III	0.00% 0	53.33% 8	13.33% 2	33.33% 5	0.00% 0	0.00% 0	0.00% 0	15
Phase IV	46.67% 7	20.00% 3	6.67% 1	6.67% 1	0.00% 0	6.67% 1	13.33% 2	15


Industry DNA Sampling

Q4 What is the average rate of DNA sample acquisition for trials with U.S. sites only? Please base your answers on actual data using the following calculation: (# of DNA samples obtained) / (# of subjects enrolled in the trials)

Answered: 13 Skipped: 3



Industry DNA Sampling




Average rate								
	0%	<50%	50-69%	70-99%	ALWAYS MANDATORY	DO NOT KNOW	NOT APPLICABLE	TOTAL
Phase I (Healthy Volunteers)	0.00%	7.69%	15.38%	38.46%	15.38%	0.00%	23.08%	13
Phase I (Diseased Patients)	7.69%	7.69%	23.08%	53.85%	0.00%	0.00%	7.69%	13
Phase II	0.00%	15.38%	15.38%	61.54%	0.00%	0.00%	7.69%	13
Phase III	0.00%	15.38%	38.46%	30.77%	0.00%	0.00%	15.38%	13
Phase IV	0.00%	7.69%	7.69%	15.38%	0.00%	30.77%	38.46%	13

Based upon					
	8-15 TRIALS	16-50 TRIALS	> 50 TRIALS	ESTIMATION	TOTAL
Phase I (Healthy Volunteers)	20.00%	40.00%	10.00%	30.00%	10
Phase I (Diseased Patients)	36.36%	27.27%	0.00%	36.36%	11
Phase II	54.55%	9.09%	0.00%	36.36%	11
Phase III	27.27%	9.09%	0.00%	63.64%	11
Phase IV	0.00%	0.00%	0.00%	100.00%	6


Industry DNA Sampling

Q5 What is the average rate of DNA sample acquisition for global trials (i.e., trials with both U.S. + Ex-U.S. sites)? Please base your answers on actual data using the following calculation: (# of DNA samples obtained) / (# of subjects enrolled in the trials)

Answered: 15 Skipped: 1



Industry DNA Sampling




Average rate								
	0%	<50%	50-69%	70-99%	ALWAYS MANDATORY	DO NOT KNOW	NOT APPLICABLE	TOTAL
Phase I (Healthy Volunteers)	0.00%	7.14%	14.29%	35.71%	14.29%	0.00%	28.57%	14
Phase I (Diseased Patients)	7.14%	7.14%	35.71%	28.57%	0.00%	0.00%	21.43%	14
Phase II	0.00%	35.71%	21.43%	35.71%	0.00%	0.00%	7.14%	14
Phase III	0.00%	6.67%	60.00%	26.67%	0.00%	0.00%	6.67%	15
Phase IV	0.00%	33.33%	16.67%	8.33%	0.00%	25.00%	16.67%	12

Based upon					
	8-15 TRIALS	16-50 TRIALS	> 50 TRIALS	ESTIMATION	TOTAL
Phase I (Healthy Volunteers)	30.00%	10.00%	20.00%	40.00%	10
Phase I (Diseased Patients)	30.00%	10.00%	10.00%	50.00%	10
Phase II	53.85%	7.69%	7.69%	30.77%	13
Phase III	46.15%	7.69%	0.00%	46.15%	13
Phase IV	0.00%	0.00%	0.00%	100.00%	5


Industry DNA Sampling

Q6 For global trials (i.e., trials with both U.S. + Ex-U.S. sites), what percentage of sites participate in DNA sample collection? Please base your answers on actual data using the following calculation: (# of sites with DNA collection) / (# of sites in trial)

Answered: 10 Skipped: 6



Industry DNA Sampling




Average rate								
	0%	<50%	50-69%	70-99%	ALWAYS MANDATORY	DO NOT KNOW	NOT APPLICABLE	TOTAL
Phase I (Healthy Volunteers)	0.00% 0	0.00% 0	11.11% 1	44.44% 4	22.22% 2	11.11% 1	11.11% 1	9
Phase I (Diseased Patients)	0.00% 0	0.00% 0	11.11% 1	55.56% 5	0.00% 0	11.11% 1	22.22% 2	9
Phase II	0.00% 0	0.00% 0	33.33% 3	44.44% 4	0.00% 0	11.11% 1	11.11% 1	9
Phase III	0.00% 0	0.00% 0	30.00% 3	50.00% 5	0.00% 0	10.00% 1	10.00% 1	10
Phase IV	0.00% 0	0.00% 0	12.50% 1	25.00% 2	0.00% 0	37.50% 3	25.00% 2	8

Based upon					
	8-15 TRIALS	16-50 TRIALS	> 50 TRIALS	ESTIMATION	TOTAL
Phase I (Healthy Volunteers)	14.29% 1	28.57% 2	14.29% 1	42.86% 3	7
Phase I (Diseased Patients)	42.86% 3	14.29% 1	0.00% 0	42.86% 3	7
Phase II	57.14% 4	0.00% 0	14.29% 1	28.57% 2	7
Phase III	50.00% 4	12.50% 1	0.00% 0	37.50% 3	8
Phase IV	0.00% 0	0.00% 0	0.00% 0	100.00% 3	3


Industry DNA Sampling

Q7 Among sites that allow DNA collection in global trials (trials with both U.S. + Ex-U.S. sites), what is the average rate of subject participation in optional DNA sample collection? Please base your answers on actual data using the following calculation: $(\# \text{ of DNA samples obtained}) / [(\# \text{ of subjects in the trial}) - (\# \text{ of subjects from sites that did not allow DNA sampling})]$

Answered: 10 Skipped: 6



Industry DNA Sampling



Average rate								
	0%	<50%	50-69%	70-99%	ALWAYS MANDATORY	DO NOT KNOW	NOT APPLICABLE	TOTAL
Phase I (Healthy Volunteers)	0.00%	0.00%	10.00%	50.00%	20.00%	10.00%	10.00%	10
Phase I (Diseased Patients)	0.00%	0.00%	20.00%	50.00%	0.00%	10.00%	20.00%	10
Phase II	0.00%	0.00%	30.00%	50.00%	0.00%	10.00%	10.00%	10
Phase III	0.00%	0.00%	20.00%	60.00%	0.00%	10.00%	10.00%	10
Phase IV	0.00%	0.00%	0.00%	28.57%	0.00%	57.14%	14.29%	7

Based upon					
	8-15 TRIALS	16-50 TRIALS	> 50 TRIALS	ESTIMATION	TOTAL
Phase I (Healthy Volunteers)	0.00%	37.50%	25.00%	37.50%	8
Phase I (Diseased Patients)	37.50%	12.50%	12.50%	37.50%	8
Phase II	50.00%	12.50%	12.50%	25.00%	8
Phase III	75.00%	12.50%	0.00%	12.50%	8
Phase IV	0.00%	0.00%	0.00%	100.00%	2


Industry DNA Sampling

Q8 What are the DNA sample collection rates for global trials (U.S. + Ex-U.S.) conducted in the following therapeutic areas? Calculate from trials conducted with diseased patients only Please base your answers on actual data using the following calculation: (# of DNA samples obtained) / (# of subjects enrolled in the trial)

Answered: 12 Skipped: 4



Industry DNA Sampling




Average rate								
	0%	<50%	50-69%	70-99%	ALWAYS MANDATORY	DO NOT KNOW	NOT APPLICABLE	TOTAL
Allergy/ Respiratory	0.00% 0	0.00% 0	50.00% 5	20.00% 2	0.00% 0	0.00% 0	30.00% 3	10
Cardiovascular/ Renal	0.00% 0	11.11% 1	33.33% 3	44.44% 4	0.00% 0	0.00% 0	11.11% 1	9
Infectious Diseases	0.00% 0	0.00% 0	50.00% 4	0.00% 0	0.00% 0	12.50% 1	37.50% 3	8
Metabolic Disease	0.00% 0	0.00% 0	25.00% 2	25.00% 2	0.00% 0	25.00% 2	25.00% 2	8
Gastrointestinal	0.00% 0	14.29% 1	28.57% 2	0.00% 0	0.00% 0	28.57% 2	28.57% 2	7
Oncology/ Hematology	0.00% 0	8.33% 1	58.33% 7	25.00% 3	0.00% 0	0.00% 0	8.33% 1	12
Immunology	0.00% 0	18.18% 2	27.27% 3	27.27% 3	0.00% 0	0.00% 0	27.27% 3	11
Neuroscience	0.00% 0	0.00% 0	44.44% 4	44.44% 4	0.00% 0	0.00% 0	11.11% 1	9
Women's/Men's Health	0.00% 0	0.00% 0	28.57% 2	0.00% 0	0.00% 0	14.29% 1	57.14% 4	7
Muscular Skeletal	0.00% 0	0.00% 0	25.00% 2	12.50% 1	0.00% 0	12.50% 1	50.00% 4	8

Based upon					
	8-15 TRIALS	16-50 TRIALS	> 50 TRIALS	ESTIMATION	TOTAL
Allergy/ Respiratory	14.29% 1	28.57% 2	0.00% 0	57.14% 4	7
Cardiovascular/ Renal	50.00% 3	16.67% 1	0.00% 0	33.33% 2	6
Infectious Diseases	50.00% 2	0.00% 0	0.00% 0	50.00% 2	4
Metabolic Disease	75.00% 3	0.00% 0	0.00% 0	25.00% 1	4
Gastrointestinal	66.67% 2	0.00% 0	0.00% 0	33.33% 1	3
Oncology/ Hematology	50.00% 5	10.00% 1	10.00% 1	30.00% 3	10
Immunology	16.67% 1	16.67% 1	0.00% 0	66.67% 4	6
Neuroscience	50.00% 4	25.00% 2	0.00% 0	25.00% 2	8
Women's/Men's Health	0.00% 0	0.00% 0	0.00% 0	100.00% 2	2
Muscular Skeletal	50.00% 1	0.00% 0	0.00% 0	50.00% 1	2

Industry DNA Sampling

Q9 For trials with optional DNA sampling, does your company consider whether sites allow participation in DNA sampling when selecting sites?

Answered: 14 Skipped: 2




ANSWER CHOICES	RESPONSES
Routinely	0.00% 0
Sometimes	50.00% 7
Never	50.00% 7
Do not know	0.00% 0
Not applicable	0.00% 0
TOTAL	14


Industry DNA Sampling

Q10 For studies with low collection rates (<50%), classify by importance what accounts for the missing samples?

Answered: 11 Skipped: 5



Industry DNA Sampling



	MAJOR	INTERMEDIATE	MINOR	DO NOT KNOW	N/A	TOTAL
Health Authority rejection of DNA sub-study	27.27% 3	18.18% 2	36.36% 4	9.09% 1	9.09% 1	11
IRB/EC rejection of DNA sub-study	63.64% 7	18.18% 2	9.09% 1	0.00% 0	9.09% 1	11
Investigator choosing not to participate	36.36% 4	9.09% 1	36.36% 4	9.09% 1	9.09% 1	11
Investigational staff discouraging participation in DNA sub-study	9.09% 1	0.00% 0	36.36% 4	54.55% 6	0.00% 0	11
Investigational staff not encouraging participation in DNA sub-study	18.18% 2	36.36% 4	0.00% 0	45.45% 5	0.00% 0	11
Wording of the DNA Informed consent (e.g., readability, how procedures are described)	9.09% 1	18.18% 2	45.45% 5	27.27% 3	0.00% 0	11
Subjects opting out of or not consenting to DNA sub-study	18.18% 2	27.27% 3	36.36% 4	18.18% 2	0.00% 0	11
Influence of other study participants where consent is given in a group setting	10.00% 1	10.00% 1	10.00% 1	50.00% 5	20.00% 2	10

Industry DNA Sampling

Q11 Regarding your responses to the question above (#10), please elaborate:


Answered: 8 Skipped: 8

ANSWER CHOICES	RESPONSES	
Health Authority rejection of DNA sub-study	62.50%	5
IRB/EC rejection of DNA sub-study	75.00%	6
Investigator choosing not to participate	50.00%	4
Investigational staff discouraging participation in DNA sub-study	50.00%	4
Investigational staff not encouraging participation in DNA sub-study	37.50%	3
Wording of the DNA Informed consent (e.g., readability, how procedures are described)	62.50%	5
Subjects opting out of or not consenting to DNA sub-study	62.50%	5
Influence of other study participants where consent is given in a group setting	62.50%	5


Industry DNA Sampling

Q12 For studies with intermediate collection rates (50-70%), classify by importance what accounts for the missing samples?

Answered: 11 Skipped: 5



Industry DNA Sampling



	MAJOR	INTERMEDIATE	MINOR	DO NOT KNOW	N/A	TOTAL
Health Authority rejection of DNA sub-study	27.27% 3	18.18% 2	27.27% 3	18.18% 2	9.09% 1	11
IRB/EC rejection of DNA sub-study	36.36% 4	45.45% 5	9.09% 1	0.00% 0	9.09% 1	11
Investigator choosing not to participate	36.36% 4	9.09% 1	27.27% 3	18.18% 2	9.09% 1	11
Investigational staff discouraging participation in DNA sub-study	9.09% 1	0.00% 0	45.45% 5	36.36% 4	9.09% 1	11
Investigational staff not encouraging participation in DNA sub-study	9.09% 1	45.45% 5	9.09% 1	27.27% 3	9.09% 1	11
Wording of the DNA Informed consent (e.g., readability, how procedures are described)	0.00% 0	9.09% 1	54.55% 6	27.27% 3	9.09% 1	11
Subjects opting out of or not consenting to DNA sub-study	27.27% 3	9.09% 1	45.45% 5	9.09% 1	9.09% 1	11
Influence of other study participants where consent is given in a group setting	0.00% 0	9.09% 1	27.27% 3	45.45% 5	18.18% 2	11

Industry DNA Sampling

Q13 Regarding your responses to the question above (#12), please elaborate:


Answered: 6 Skipped: 10

ANSWER CHOICES	RESPONSES	
Health Authority rejection of DNA sub-study	83.33%	5
IRB/EC rejection of DNA sub-study	66.67%	4
Investigator choosing not to participate	33.33%	2
Investigational staff discouraging participation in DNA sub-study	33.33%	2
Investigational staff not encouraging participation in DNA sub-study	33.33%	2
Wording of the DNA Informed consent (e.g., readability, how procedures are described)	50.00%	3
Subjects opting out of or not consenting to DNA sub-study	50.00%	3
Influence of other study participants where consent is given in a group setting	16.67%	1


Industry DNA Sampling

Q14 For studies with high collection rates (>70%), classify by importance what accounts for the missing samples?

Answered: 11 Skipped: 5



Industry DNA Sampling



	MAJOR	INTERMEDIATE	MINOR	DO NOT KNOW	N/A	TOTAL
Health Authority rejection of DNA sub-study	45.45% 5	9.09% 1	9.09% 1	18.18% 2	18.18% 2	11
IRB/EC rejection of DNA sub-study	36.36% 4	18.18% 2	27.27% 3	9.09% 1	9.09% 1	11
Investigator choosing not to participate	18.18% 2	9.09% 1	36.36% 4	27.27% 3	9.09% 1	11
Investigational staff discouraging participation in DNA sub-study	18.18% 2	0.00% 0	36.36% 4	36.36% 4	9.09% 1	11
Investigational staff not encouraging participation in DNA sub-study	18.18% 2	18.18% 2	18.18% 2	36.36% 4	9.09% 1	11
Wording of the DNA Informed consent (e.g., readability, how procedures are described)	9.09% 1	9.09% 1	36.36% 4	36.36% 4	9.09% 1	11
Subjects opting out of or not consenting to DNA sub-study	54.55% 6	0.00% 0	27.27% 3	9.09% 1	9.09% 1	11
Influence of other study participants where consent is given in a group setting	0.00% 0	9.09% 1	18.18% 2	54.55% 6	18.18% 2	11

Industry DNA Sampling

Q15 Regarding your responses to the question above (#14), please elaborate:


Answered: 5 Skipped: 11

ANSWER CHOICES	RESPONSES	
Health Authority rejection of DNA sub-study	60.00%	3
IRB/EC rejection of DNA sub-study	40.00%	2
Investigator choosing not to participate	40.00%	2
Investigational staff discouraging participation in DNA sub-study	20.00%	1
Investigational staff not encouraging participation in DNA sub-study	20.00%	1
Wording of the DNA Informed consent (e.g., readability, how procedures are described)	20.00%	1
Subjects opting out of or not consenting to DNA sub-study	60.00%	3
Influence of other study participants where consent is given in a group setting	0.00%	0


Industry DNA Sampling

Q16 What are the reasons for a Health Authority (e.g., FDA, EMEA, MHRA, PMDA, Health Canada, etc.) not approving a DNA sub-study?

Answered: 10 Skipped: 6



Industry DNA Sampling




■ Repeatedly
 ■ Occasionally
 ■ Do not know

	REPEATEDLY	OCCASIONALLY	DO NOT KNOW	TOTAL
Country laws prohibit DNA collection	14.29% 1	42.86% 3	42.86% 3	7
Country has never approved DNA sub-study before (i.e., no experience)	12.50% 1	50.00% 4	37.50% 3	8
Consent for DNA sampling does not meet Health Authority standards	25.00% 2	25.00% 2	50.00% 4	8
Country regulations do not permit storage/banking	44.44% 4	33.33% 3	22.22% 2	9
Country regulations do not permit export	33.33% 3	55.56% 5	11.11% 1	9
Country regulations require a specific research plan (objections to unspecified or exploratory research)	55.56% 5	22.22% 2	22.22% 2	9
Country regulations require a separate protocol for the DNA sub-study	30.00% 3	50.00% 5	20.00% 2	10
Country regulations on genetic testing for diagnostic purposes are confused with genetic research purposes	0.00% 0	88.89% 8	11.11% 1	9
Country regulations require return of research data	10.00% 1	70.00% 7	20.00% 2	10
Country regulations require genetic counseling to be provided	0.00% 0	62.50% 5	37.50% 3	8


Industry DNA Sampling

Q17 What are the reasons for an IRB/IEC not approving a DNA sub-study?

Answered: 11 Skipped: 5



Industry DNA Sampling



	REPEATEDLY	OCCASIONALLY	DO NOT KNOW	TOTAL
Country laws prohibit DNA collection	12.50% 1	62.50% 5	25.00% 2	8
Country has never approved DNA sub-study before (i.e., no experience)	11.11% 1	66.67% 6	22.22% 2	9
Consent for DNA sampling does not meet Health Authority standards	44.44% 4	33.33% 3	22.22% 2	9
Country regulations do not permit storage/banking	20.00% 2	60.00% 6	20.00% 2	10
Country regulations do not permit export	10.00% 1	80.00% 8	10.00% 1	10
Country regulations require a specific research plan (objections to unspecified or exploratory research)	60.00% 6	40.00% 4	0.00% 0	10
Country regulations require a separate protocol for the DNA sub-study	10.00% 1	90.00% 9	0.00% 0	10
Country regulations on genetic testing for diagnostic purposes are confused with genetic research purposes	10.00% 1	80.00% 8	10.00% 1	10
Country regulations require return of research data	18.18% 2	72.73% 8	9.09% 1	11
Country regulations require genetic counseling to be provided	0.00% 0	77.78% 7	22.22% 2	9

Industry DNA Sampling

Q18 What countries currently have specific hurdles for collection of DNA samples? Please specify first whether a country has typical hurdles for DNA collection and storage (first column of drop-down menus). If the country has typical hurdle, please use the list of hurdles on the right panel, and insert the hurdle number into the drop-down boxes. For each hurdle and country, please specify how often it is encountered. If there are hurdles that are not specified, or countries that are not listed, please use the free-text box at the bottom of the page for additional information. Leave blank boxes (except for the 'Hurdles?' box) whenever you do not have information to add. TIP: you can use the Tab key to navigate between the drop-down boxes, and the up and down arrows to assign values. Use the Shift-Tab combination to move backwards. List of countries A-J:

Answered: 13 Skipped: 3

▲ We're sorry. We cannot display a chart for a question with this many options.

Hurdles?	NO		YES		TOTAL										
Argentina	25.00%	1	75.00%	3	4										
Australia	25.00%	1	75.00%	3	4										
Austria	100.00%	3	0.00%	0	3										
Belgium	75.00%	3	25.00%	1	4										
Brazil	0.00%	0	100.00%	7	7										
Canada	100.00%	4	0.00%	0	4										
China	0.00%	0	100.00%	10	10										
Chile	50.00%	2	50.00%	2	4										
Colombia	100.00%	2	0.00%	0	2										
Costa Rico	33.33%	1	66.67%	2	3										
Czech Rep	75.00%	3	25.00%	1	4										
Denmark	100.00%	4	0.00%	0	4										
Finland	33.33%	1	66.67%	2	3										
France	14.29%	1	85.71%	6	7										
Germany	100.00%	4	0.00%	0	4										
Greece	75.00%	3	25.00%	1	4										
Hong Kong	100.00%	2	0.00%	0	2										
Hungary	66.67%	2	33.33%	1	3										
Iceland	0.00%	0	100.00%	2	2										
India	0.00%	0	100.00%	6	6										
Israel	0.00%	0	100.00%	5	5										
Italy	25.00%	2	75.00%	6	8										
Japan	16.67%	1	83.33%	5	6										
Hurdle 1	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15

Industry DNA Sampling

Argentina	0.00% 0	100.00% 2	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Australia	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Austria	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Belgium	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Brazil	57.14% 4	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	14.29% 1	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Canada	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	100.00% 1	0.00% 0	0.00% 0
China	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	70.00% 7	30.00% 3	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Chile	0.00% 0	50.00% 1	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Colombia	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Costa Rico	100.00% 1	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Czech Rep	0.00% 0	100.00% 1	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Denmark	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Finland	50.00% 1	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	50.00% 1
France	25.00% 1	25.00% 1	0.00% 0	25.00% 1	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Germany	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Greece	0.00% 0	0.00% 0	0.00% 0	100.00% 1	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Hong Kong	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Hungary	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Iceland	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	50.00% 1	0.00% 0	0.00% 0	50.00% 1	0.00% 0	0.00% 0
India	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	60.00% 3	40.00% 2	0.00% 0	0.00% 0	0.00% 0
Israel	0.00% 0	25.00% 1	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	25.00% 1	0.00% 0	0.00% 0	0.00% 0
Italy	0.00% 0	0.00% 0	0.00% 0	25.00% 1	0.00% 0	25.00% 1	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	25.00% 1	0.00% 0
Japan	0.00% 0	50.00% 2	0.00% 0	0.00% 0	0.00% 0	50.00% 2	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0

Encounter				
	ALWAYS	OFTEN	RARELY	TOTAL
Argentina		0.00% 0	100.00% 2	0.00% 0 2
Australia		0.00% 0	0.00% 0	100.00% 1 1
Austria		0.00% 0	0.00% 0	0.00% 0 0
Belgium		0.00% 0	0.00% 0	100.00% 1 1
Brazil		71.43% 5	28.57% 2	0.00% 0 7
Canada		0.00% 0	0.00% 0	100.00% 1 1
China		100.00% 9	0.00% 0	0.00% 0 9
Chile		0.00% 0	100.00% 2	0.00% 0 2
Colombia		0.00% 0	0.00% 0	0.00% 0 0
Costa Rico		50.00% 1	50.00% 1	0.00% 0 2
Czech Rep		0.00% 0	0.00% 0	100.00% 1 1
Denmark		0.00% 0	0.00% 0	0.00% 0 0
Finland		0.00% 0	100.00% 2	0.00% 0 2

Industry DNA Sampling

France	40.00%	20.00%	40.00%	5
	2	1	2	
Germany	0.00%	0.00%	0.00%	0
	0	0	0	
Greece	100.00%	0.00%	0.00%	1
	1	0	0	
Hong Kong	0.00%	0.00%	0.00%	0
	0	0	0	
Hungary	0.00%	0.00%	100.00%	1
	0	0	1	
Iceland	100.00%	0.00%	0.00%	2
	2	0	0	
India	83.33%	16.67%	0.00%	6
	5	1	0	
Israel	75.00%	25.00%	0.00%	4
	3	1	0	
Italy	40.00%	40.00%	20.00%	5
	2	2	1	
Japan	0.00%	100.00%	0.00%	4
	0	4	0	

Hurdle 2																
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
Argentina	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Australia	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Austria	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Belgium	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Brazil	0.00%	14.29%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	14.29%	0.00%	14.29%	14.29%	14.29%	0.00%	0.00%	0.00%
	0	1	0	0	0	0	0	0	1	0	1	1	1	0	0	0
Canada	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
China	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chile	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Colombia	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Costa Rico	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Czech Rep	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Denmark	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Finland	0.00%	50.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	50.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0
France	0.00%	50.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	50.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0
Germany	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Greece	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hong Kong	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hungary	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Iceland	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
India	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Israel	0.00%	0.00%	0.00%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
Italy	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	50.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
Japan	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	50.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0

Encounter			
	ALWAYS	OFTEN	RARELY
Argentina	100.00%	0.00%	0.00%
	1	0	0
Australia	0.00%	0.00%	0.00%
	0	0	0

Industry DNA Sampling

Austria	0.00%	0.00%	0.00%	0
	0	0	0	0
Belgium	0.00%	0.00%	0.00%	0
	0	0	0	0
Brazil	71.43%	28.57%	0.00%	7
	5	2	0	
Canada	0.00%	0.00%	0.00%	0
	0	0	0	0
China	0.00%	0.00%	0.00%	0
	0	0	0	0
Chile	0.00%	0.00%	0.00%	0
	0	0	0	0
Colombia	0.00%	0.00%	0.00%	0
	0	0	0	0
Costa Rico	0.00%	0.00%	0.00%	0
	0	0	0	0
Czech Rep	0.00%	0.00%	0.00%	0
	0	0	0	0
Denmark	0.00%	0.00%	0.00%	0
	0	0	0	0
Finland	0.00%	100.00%	0.00%	2
	0	2	0	
France	50.00%	50.00%	0.00%	2
	1	1	0	
Germany	0.00%	0.00%	0.00%	0
	0	0	0	0
Greece	0.00%	0.00%	0.00%	0
	0	0	0	0
Hong Kong	0.00%	0.00%	0.00%	0
	0	0	0	0
Hungary	0.00%	0.00%	0.00%	0
	0	0	0	0
Iceland	0.00%	0.00%	0.00%	0
	0	0	0	0
India	0.00%	0.00%	0.00%	0
	0	0	0	0
Israel	100.00%	0.00%	0.00%	1
	1	0	0	
Italy	100.00%	0.00%	0.00%	2
	2	0	0	
Japan	0.00%	100.00%	0.00%	2
	0	2	0	

Hurdle 3																	
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
Argentina	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Australia	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Austria	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Belgium	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Brazil	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	25.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Canada	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
China	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Chile	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Colombia	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Costa Rico	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Czech Rep	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Denmark	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Finland	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
France	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Germany	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Industry DNA Sampling

Greece	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hong Kong	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Hungary	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Iceland	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
India	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Israel	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Italy	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	50.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Japan	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Encounter				
	ALWAYS	OFTEN	RARELY	TOTAL
Argentina		0.00%	0.00%	0.00%
		0	0	0
Australia		0.00%	0.00%	0.00%
		0	0	0
Austria		0.00%	0.00%	0.00%
		0	0	0
Belgium		0.00%	0.00%	0.00%
		0	0	0
Brazil		75.00%	25.00%	0.00%
		3	1	4
Canada		0.00%	0.00%	0.00%
		0	0	0
China		0.00%	0.00%	0.00%
		0	0	0
Chile		0.00%	0.00%	0.00%
		0	0	0
Colombia		0.00%	0.00%	0.00%
		0	0	0
Costa Rico		0.00%	0.00%	0.00%
		0	0	0
Czech Rep		0.00%	0.00%	0.00%
		0	0	0
Denmark		0.00%	0.00%	0.00%
		0	0	0
Finland		0.00%	100.00%	0.00%
		0	1	1
France		50.00%	0.00%	50.00%
		1	0	1
Germany		0.00%	0.00%	0.00%
		0	0	0
Greece		0.00%	0.00%	0.00%
		0	0	0
Hong Kong		0.00%	0.00%	0.00%
		0	0	0
Hungary		0.00%	0.00%	0.00%
		0	0	0
Iceland		0.00%	0.00%	0.00%
		0	0	0
India		0.00%	0.00%	0.00%
		0	0	0
Israel		100.00%	0.00%	0.00%
		1	0	1
Italy		100.00%	0.00%	0.00%
		2	0	2
Japan		0.00%	0.00%	0.00%
		0	0	0

Industry DNA Sampling

Q19 List of countries K-V:

Answered: 11 Skipped: 5

▲ We're sorry. We cannot display a chart for a question with this many options.

Hurdles?		NO		YES		TOTAL	
Malaysia		0.00%	0	100.00%	2		2
Mexico		50.00%	2	50.00%	2		4
Netherlands		60.00%	3	40.00%	2		5
New Zealand		66.67%	2	33.33%	1		3
Norway		80.00%	4	20.00%	1		5
Peru		100.00%	3	0.00%	0		3
Poland		33.33%	1	66.67%	2		3
Portugal		66.67%	2	33.33%	1		3
Puerto Rico		100.00%	1	0.00%	0		1
Russia		40.00%	2	60.00%	3		5
Singapore		100.00%	2	0.00%	0		2
South Africa		20.00%	1	80.00%	4		5
Spain		40.00%	2	60.00%	3		5
Sweden		0.00%	0	100.00%	4		4
Switzerland		100.00%	3	0.00%	0		3
Slovakia		100.00%	3	0.00%	0		3
Taiwan		0.00%	0	100.00%	3		3
Thailand		0.00%	0	100.00%	3		3
USA		12.50%	1	87.50%	7		8
UK		100.00%	3	0.00%	0		3
Ukraine		50.00%	1	50.00%	1		2
Venezuela		100.00%	1	0.00%	0		1

Hurdle 1																	
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
Malaysia	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	50.00%	0.00%	0.00%	50.00%	0.00%	0.00%	0.00%	0.00%
Mexico	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	50.00%	50.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Netherlands	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
New Zealand	0.00%	0.00%	0.00%	0.00%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Norway	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Peru	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Poland	0.00%	50.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	50.00%	0.00%	0.00%	0.00%	0.00%
Portugal	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Puerto Rico	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Industry DNA Sampling

Russia	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	66.67% 2	33.33% 1	0.00% 0	0.00% 0	0.00% 0
Singapore	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
South Africa	0.00% 0	33.33% 1	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Spain	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	33.33% 1	0.00% 0	0.00% 0	33.33% 1	0.00% 0
Sweden	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Switzerland	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Slovakia	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Taiwan	0.00% 0	66.67% 2	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Thailand	0.00% 0	33.33% 1	0.00% 0	0.00% 0	0.00% 0	33.33% 1	33.33% 1	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
USA	0.00% 0	14.29% 1	0.00% 0	0.00% 0	0.00% 0	42.86% 3	14.29% 1	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	14.29% 1	0.00% 0
UK	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Ukraine	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	100.00% 1	0.00% 0	0.00% 0	0.00% 0	0.00% 0
Venezuela	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0	0.00% 0

Encounter					
	ALWAYS	OFTEN	RARELY	TOTAL	
Malaysia		100.00% 2	0.00% 0	0.00% 0	2
Mexico		100.00% 2	0.00% 0	0.00% 0	2
Netherlands		50.00% 1	50.00% 1	0.00% 0	2
New Zealand		0.00% 0	0.00% 0	0.00% 0	0
Norway		100.00% 1	0.00% 0	0.00% 0	1
Peru		0.00% 0	0.00% 0	0.00% 0	0
Poland		50.00% 1	50.00% 1	0.00% 0	2
Portugal		100.00% 1	0.00% 0	0.00% 0	1
Puerto Rico		100.00% 1	0.00% 0	0.00% 0	1
Russia		100.00% 3	0.00% 0	0.00% 0	3
Singapore		0.00% 0	0.00% 0	0.00% 0	0
South Africa		0.00% 0	100.00% 3	0.00% 0	3
Spain		66.67% 2	0.00% 0	33.33% 1	3
Sweden		33.33% 1	66.67% 2	0.00% 0	3
Switzerland		0.00% 0	0.00% 0	0.00% 0	0
Slovakia		0.00% 0	0.00% 0	0.00% 0	0
Taiwan		66.67% 2	33.33% 1	0.00% 0	3
Thailand		50.00% 1	50.00% 1	0.00% 0	2
USA		16.67% 1	16.67% 1	66.67% 4	6
UK		0.00% 0	0.00% 0	0.00% 0	0
Ukraine		100.00% 1	0.00% 0	0.00% 0	1
Venezuela		0.00% 0	0.00% 0	0.00% 0	0

Hurdle 2																
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16

Industry DNA Sampling

Malaysia	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Mexico	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Netherlands	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	0.00%
New Zealand	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Norway	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Peru	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Poland	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Portugal	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Puerto Rico	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Russia	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Singapore	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
South Africa	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Spain	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Sweden	100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Switzerland	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Slovakia	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Taiwan	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Thailand	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	100.00%	0.00%	0.00%	0.00%
USA	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	50.00%	0.00%	0.00%	0.00%
UK	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Ukraine	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Venezuela	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Encounter	ALWAYS	OFTEN	RARELY	TOTAL
Malaysia	0.00%	0.00%	0.00%	0
Mexico	0.00%	0.00%	0.00%	0
Netherlands	0.00%	100.00%	0.00%	1
New Zealand	0.00%	0.00%	0.00%	0
Norway	0.00%	0.00%	0.00%	0
Peru	0.00%	0.00%	0.00%	0
Poland	0.00%	100.00%	0.00%	1
Portugal	0.00%	0.00%	0.00%	0
Puerto Rico	0.00%	0.00%	0.00%	0
Russia	0.00%	0.00%	0.00%	0
Singapore	0.00%	0.00%	0.00%	0
South Africa	0.00%	0.00%	0.00%	0
Spain	0.00%	0.00%	0.00%	0
Sweden	0.00%	100.00%	0.00%	1

Industry DNA Sampling

Switzerland	0.00%	0.00%	0.00%	0
Slovakia	0.00%	0.00%	0.00%	0
Taiwan	100.00%	0.00%	0.00%	1
Thailand	0.00%	100.00%	0.00%	1
USA	0.00%	0.00%	100.00%	2
UK	0.00%	0.00%	0.00%	0
Ukraine	0.00%	0.00%	0.00%	0
Venezuela	0.00%	0.00%	0.00%	0

Hurdle 3																	
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17
Malaysia	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Mexico	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Netherlands	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
New Zealand	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Norway	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Peru	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Poland	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Portugal	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Puerto Rico	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Russia	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Singapore	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
South Africa	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Spain	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Sweden	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Switzerland	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Slovakia	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Taiwan	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Thailand	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
USA	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
UK	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Ukraine	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Venezuela	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Encounter				
	ALWAYS	OFTEN	RARELY	TOTAL
Malaysia	0.00%	0.00%	0.00%	0
Mexico	0.00%	0.00%	0.00%	0
Netherlands	0.00%	0.00%	0.00%	0
New Zealand	0.00%	0.00%	0.00%	0
Norway	0.00%	0.00%	0.00%	0

Industry DNA Sampling

Peru	0.00% 0	0.00% 0	0.00% 0	0
Poland	0.00% 0	0.00% 0	0.00% 0	0
Portugal	0.00% 0	0.00% 0	0.00% 0	0
Puerto Rico	0.00% 0	0.00% 0	0.00% 0	0
Russia	0.00% 0	0.00% 0	0.00% 0	0
Singapore	0.00% 0	0.00% 0	0.00% 0	0
South Africa	0.00% 0	0.00% 0	0.00% 0	0
Spain	0.00% 0	0.00% 0	0.00% 0	0
Sweden	0.00% 0	100.00% 1	0.00% 0	1
Switzerland	0.00% 0	0.00% 0	0.00% 0	0
Slovakia	0.00% 0	0.00% 0	0.00% 0	0
Taiwan	0.00% 0	0.00% 0	0.00% 0	0
Thailand	0.00% 0	0.00% 0	0.00% 0	0
USA	0.00% 0	0.00% 0	0.00% 0	0
UK	0.00% 0	0.00% 0	0.00% 0	0
Ukraine	0.00% 0	0.00% 0	0.00% 0	0
Venezuela	0.00% 0	0.00% 0	0.00% 0	0